The U.S. Food and Drug Administration is months away from approving the first biosimilar drugs, but a bill advanced by a legislative committee Monday would help Utah prepare for that day.
House Health and Human Services Committee members signed off on HB 279, sponsored by Rep. Brad Dee, R-Washington Terrace. It now moves to the full House.